New Drugs and Devices for HF Therapy

Published: 31 July 2020

  • Views:

    Views Icon 306
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This session was part of the 1st e-SPACE Heart Failure Meeting held virtually on July 11-14th 2020 and focuses on novel drugs and devices changing the treatment paradigm in Heart Failure management.

Agenda

  • Omecamtiv Mecarbil for Chronic HF - John Teerlink (University of San Francisco, San Francisco, US)
  • Devices for Functional MR beyond Mitraclip - Ralph Stephan von Bardeleben (University of Mainz, Mainz, DE)
  • Devices for Baroreflex Stimulation - Andrew Coats (Monash University, Melbourne, AU)
  • More on New Drugs and Devices on the Horizon - Stefan Anker (Charite University, Berlin, DE)

More from this programme

Part 1

Omecamtiv Mecarbil for Chronic HF

Part 2

Devices for Functional MR beyond Mitraclip

Part 3

Devices for Baroreflex Stimulation

Part 4

More on New Drugs and Devices on the Horizon

Faculty Biographies

John R Teerlink

John R Teerlink

Director

Dr John R Teerlink is Director of the Heart Failure Program and of the Clinical Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center in San Francisco, California. 

Dr Teerlink graduated from Swarthmore College with Highest Honors in Comparative Religious Studies and Cellular Biology. After receiving his medical degree from Harvard Medical School, he completed an internal medicine residency at the University of California San Francisco (UCSF).

View full profile